



(11)

EP 0 784 684 B8

(12)

CORRECTED EUROPEAN PATENT SPECIFICATION

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 B1)

Bibliography INID code(s) 73

(51) Int Cl.:

C12N 15/13 (2006.01) **C07K 16/30** (2006.01)

C07K 16/46 (2006.01) **A61K 39/395** (2006.01)

G01N 33/574 (2006.01) **G01N 33/577** (2006.01)

G01N 33/68 (2006.01) **A61K 47/48** (2006.01)

(48) Corrigendum issued on:

26.03.2008 Bulletin 2008/13

(86) International application number:

PCT/US1995/011683

(45) Date of publication and mention

of the grant of the patent:

15.08.2007 Bulletin 2007/33

(87) International publication number:

WO 1996/008565 (21.03.1996 Gazette 1996/13)

(21) Application number: **95933105.9**

(22) Date of filing: **14.09.1995**

(54) **RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES**

REKOMBINANTPEPTIDE HERGELEITET VOM MC3 ANTIKÖRPER GEGEN BA46, VERFAHREN ZU DEREN VERWENDUNG UND VERFAHREN ZUR HUMANISIERUNG VON ANTIKÖRPERPEPTIDEN

PEPTIDES RECOMBINANTS DERIVES DE L'ANTICORPS Mc3 DIRIGE CONTRE L'ANTIGENE BA46, LEURS PROCEDES D'UTILISATION ET PROCEDES D'HUMANISATION D'ANTICORPS PEPTIDIQUES

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(74) Representative: **Roques, Sarah Elizabeth**

J.A. Kemp & Co.

14 South Square

Gray's Inn

London WC1R 5JJ (GB)

(30) Priority: **16.09.1994 US 307868**

07.06.1995 US 487598

(56) References cited:

EP-A- 0 534 742

WO-A-94/11509

(43) Date of publication of application:

23.07.1997 Bulletin 1997/30

• **MOLECULAR IMMUNOLOGY**, vol. 28, no. 4, April 1991 OXFORD, GB, pages 489-498, E. PADLAN ET AL. 'A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties.' cited in the application

(73) Proprietor: **Cancer Research Institute of Contra Costa**

New York NY 10010 (US)

• **HYBRIDOMA**, vol. 9, no. 3, June 1990 NEW YORK, NY, USA, pages 221-235, J. PETERSON ET AL. 'Biochemical and histological characterization of antigens preferentially expressed on the surface and cytoplasm of breast carcinoma cells identified by monoclonal antibodies against the human milk fat globule.' cited in the application

(72) Inventors:

• **DO COUTO, Fernando, J., R.**

Pleasanton, CA 94588 (US)

• **CERIANI, Roberto, I.**

Lafayette, CA 94549 (US)

• **PETERSON, Jerry, A.**

San Francisco, CA 94107 (US)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 784 684 B8

- | | |
|--|--|
| <ul style="list-style-type: none"> • CANCER RESEARCH, vol. 48, no. 16, 15 August 1988 PHILADELPHIA, PA, USA, pages 4664-4672, R. CERIANI ET AL. 'Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.' cited in the application • HYBRIDOMA, vol. 13, no. 3, June 1994 NEW YORK, NY, USA, pages 215-219, J. COUTO ET AL. 'Humanization of KC4G3, an anti-human carcinoma antibody.' • IMMUNOLOGY, vol. 78, no. 3, March 1993 OXFORD, GB, pages 364-370, M. VERHOEYEN ET AL. 'Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.' • ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 353, 1994 NEW YORK, NY, USA, pages 55-59, J. COUTO ET AL. 'Engineering of antibodies for breast cancer therapy: Construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3.' | <ul style="list-style-type: none"> • PROTEIN ENGINEERING, vol. 7, no. 6, June 1994 OXFORD, GB, pages 805-814, G. STUDNICKA ET AL. 'Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues.' • CANCER RESEARCH, vol. 55, no. 8, 15 April 1995 PHILADELPHIA, PA, USA, pages 1717-1722, J. COUTO ET AL. 'Anti-BA46 monoclonal antibody Mc3: Humanization using a novel positional consensus and in vivo and in vitro characterization.' |
|--|--|